Advertisement

Facteurs pronostiques des tumeurs germinales

  • S. Le Moulec
  • A. Houlgatte
Chapter
  • 193 Downloads
Part of the Monographies en urologie book series (MONOGRAPHIES)

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. 1.
    Horwich A, Alsanyari N, A’Hern R (1992) Surveillance following orchidectomy for stage I seminoma. Br J Cancer 65: 775–8PubMedGoogle Scholar
  2. 2.
    Warde P, Gospodarowicz MK, Banerjee D et al. (1997) Prognostic factor for relapse in stage I testicular seminoma treated with surveillance. J Urol 157: 1705–9PubMedGoogle Scholar
  3. 3.
    Warde P, Specht L, Horwich A et al. (2002) Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis. J Clin Oncol 20: 4448–52PubMedCrossRefGoogle Scholar
  4. 4.
    Aparicio J, Germa JR, Garcia Del Muro X et al. (2004) Risk-adapted management of stade I seminoma: the second Spanish germ cell cancer group (GG) study. New Orleans: Proc Amer Assoc Cancer Res abstract 4518Google Scholar
  5. 5.
    Albers P, Siener R, Kliesch S et al. (2003) Risk factors for relapse in clinical stage I nonseminomatous testicular germ cell tumors: results of the German Testicular Cancer Study Group Trial. J Clin Oncol 21(8): 1505–12PubMedCrossRefGoogle Scholar
  6. 6.
    Alexandre J, Fizazi K, Mahé C et al. (2001) Stage I non-seminomatous germ-cell tumours of the testis: identification of a subgroup of patients with a very low risk of relapse. Eur J Cancer 37: 576–82PubMedCrossRefGoogle Scholar
  7. 7.
    International Germ Cell Cancer Collaborative Group (1997) International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 15: 594–603Google Scholar
  8. 8.
    Bosl GJ, Bajorin D, Scheinfeld J (1997) Cancer of the testis. I De Vita VT, Hellman S, Rosenberg S, eds; cancer; Principles and practice of Oncology. 5th ed. Philadelphia; JB. Lippincott 1397–425Google Scholar
  9. 9.
    Mazumdar M, Bajorin DF, Bacik J et al. (2001) Predicting Outcome to Chemotherapy in Patients With Germ Cell Tumors: The Value of the Rate of Decline of Human Chorionic Gonadotrophin and Alpha-Fetoprotein During Therapy. J Clin Oncol 19(9): 2534–41PubMedGoogle Scholar
  10. 10.
    Fizazi K, Culine S, Kramar A et al. (2004) Early Predicted Time to Normalization of Tumor Markers Predicts Outcome in Poor-Prognosis Nonseminomatous Germ Cell Tumors. J Clin Oncol 22(19): 3868–76PubMedCrossRefGoogle Scholar
  11. 11.
    Fizazi K, Tjulandin S, Salvioni R et al. (2001) Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy-results from an international study group. J Clin Oncol 19: 2647–57PubMedGoogle Scholar
  12. 12.
    Bourguet P (2003) (2002 Standards, Options and Recommendations for the use of [18F]-FDG (PET-FDG) in cancerology). Bull Cancer 90 Spec No: S1-109, S1-109Google Scholar
  13. 13.
    Stephens AW, Gonin R, Hutchins GD et al. (1996) Positron emission tomography evaluation of residual radiographic abnormalities in postchemotherapy germ cell tumor patients. J Clin Oncol 14: 1637–41PubMedGoogle Scholar
  14. 14.
    Kollmannsberger C, Oechsle K, Dohmen BM et al. (2002) Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography with conventional assessment by computed tomography scans and serum tumor markers for the evaluation of residual masses in patients with nonseminomatous germ cell carcinoma. Cancer 94: 2353–62PubMedCrossRefGoogle Scholar
  15. 15.
    De Santis M, Becherer A, Bokemeyer C et al. (2004) 2-18 fluoro-deoxy-D-glucose positon emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial. J Clin Oncol 22: 1034–9PubMedGoogle Scholar
  16. 16.
    Steyerberg EW, Keizer HJ, Messemer JE et al. (1997) Residual pulmonary masses after chemotherapy for metastatic nonseminomatous germ cell tumor. Prediction of histology. ReHiT Study Group. Cancer 79: 345–55PubMedCrossRefGoogle Scholar
  17. 17.
    McGuire MS, Rabbani F, Mohseni H et al. (2003) The role of thoracotomy in managing postchemotherapy residual thoracic masses in patients with nonseminomatous germ cell tumours. BJU Int 91: 469–73PubMedCrossRefGoogle Scholar
  18. 18.
    Besse B, Flechon A, Caty A et al. (2005) No need for controlateral lung surgery in case of evidence of post-chemotherapy necrosis alone in residual lung masses in patients with disseminated non seminomatous germ cell tumors. Poster Discussion, ASCO Vol 23, No 16SGoogle Scholar
  19. 19.
    Fossa SD, Aass N, Ous S et al. (1989) Histology of tumor residuals following chemotherapy in patients with advanced nonseminomatous testicular cancer. J Urol 142, 1239–42PubMedGoogle Scholar
  20. 20.
    Mulders PF, Oosterhof GO, Boetes C et al. (1990) The importance of prognostic factors in the individual treatment of patients with disseminated germ cell tumours. Br J Urol 66: 425–9PubMedCrossRefGoogle Scholar
  21. 21.
    Hendry WF, A’Hern RP, Hetherington JW et al. (1993) Para-aortic lymphadenectomy after chemotherapy for metastatic non-seminomatous germ cell tumours: prognostic value and therapeutic benefit. Br J Urol 71: 208–13PubMedGoogle Scholar
  22. 22.
    Toner GC, Panicek DM, Heelan RT et al. (1990) Adjunctive surgery after chemotherapy for nonseminomatous germ cell tumors: recommendations for patient selection. J Clin Oncol 8: 1683–94PubMedGoogle Scholar
  23. 23.
    Steyerberg EW, Keizer HJ, Fossa SD et al. (1995) Prediction of residual retroperitoneal mass histology after chemotherapy for metastatic nonseminomatous germ cell tumor: multivariate analysis of individual patient data from six study groups. J Clin Oncol 13: 1177–87PubMedGoogle Scholar
  24. 24.
    Hartmann JT, Candelaria M, Kuczyk MA et al. (1997) Comparison of histological results from the resection of residual masses at different sites after chemotherapy for metastatic non-seminomatous germ cell tumours. Eur J Cancer 33: 843–47PubMedGoogle Scholar
  25. 25.
    Germa-Lluch JR, Garcia DM, X, Maroto P et al. (2002) Clinical pattern and therapeutic results achieved in 1,490 patients with germ-cell tumours of the testis: the experience of the Spanish Germ-Cell Cancer Group (GG). Eur Urol 42: 553–62PubMedGoogle Scholar
  26. 26.
    McGuire MS, Rabbani F, Mohseni H et al. (2003) The role of thoracotomy in managing postchemotherapy residual thoracic masses in patients with nonseminomatous germ cell tumours. BJU Int 91: 469–73PubMedCrossRefGoogle Scholar
  27. 27.
    Gerl A, Clemm C, Schmeller N et al. (1995) Outcome analysis after post-chemotherapy surgery in patients with non-seminomatous germ cell tumours. Ann Oncol 6: 483–8PubMedGoogle Scholar
  28. 28.
    Steyerberg EW, Gerl A, Fossa SD et al. 1998. Validity of predictions of residual retroperitoneal mass histology in nonseminomatous testicular cancer. J Clin Oncol 16: 269–274PubMedGoogle Scholar
  29. 29.
    Fizazi K, Dunant A, Oldenburg J et al. On behalf of an International Study Group. Poster Discussion ASCO 2005, Vol 23, 16SGoogle Scholar
  30. 30.
    Kuczyk, MA, Bokemeyer C, Kollmannsberger C et al. (2004) Late relapse after treatment for nonseminomatous testicular germ cell tumors according to a single center-based experience. World J Urol 22(1): 55–9PubMedGoogle Scholar
  31. 31.
    Farhat F, Culine S, Theodore C et al. (1996) Cisplatin and ifosfamide with either vinblastine or etoposide as salvage therapy for refractory or relapsing germ cell tumor patients: the Institut Gustave Roussy experience. Cancer 77: 1193–7PubMedGoogle Scholar
  32. 32.
    McCaffrey JA, Mazumdar M, Bajorin DF et al. (1997) Ifosfamide and cisplatin containing chemotherapy as first-line salvage therapy in germ cell tumors: response and survival. J Clin Oncol 15: 2559–63PubMedGoogle Scholar
  33. 33.
    Motzer RJ, Geller NL, Tan CC et al. (1991) Salvage chemotherapy for patients with germ cell tumors. The Memorial Sloan-Kettering Cancer Center experience (1979–1989). Cancer 67: 1305–10PubMedGoogle Scholar
  34. 34.
    Motzer RJ, Sheinfeld J, Mazumdar M et al. (2000) Paclitaxel, ifosfamide and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer. J Clin Oncol 18:2413–8PubMedGoogle Scholar
  35. 35.
    Fizazi K, Do Kim-Anh, Wang Xuemei et al. (2001) Phase II Study of Salvage Dose Dense Chemotherapy in Patients with Disseminated Non Seminomatous Germ Cell tumors (NSGCT). Poster ECCO. Eur J Cancer 37: 152–25Google Scholar
  36. 36.
    Fossa SD, Stenning SP, Gerl A (1999) et al. Prognostics factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumors. Br J Cancer 80: 1392–9PubMedGoogle Scholar
  37. 37.
    Lotz JP, André T, Donsimoni R et al. (1995) High dose chemotherapy with ifosfamide, carboplatin and etoposide combined with autologous bone marrow transplantation for the treatment of poor-prognosis germ cell tumors and metastatic trophoblastic disease in adults. Cancer 75: 874–85PubMedGoogle Scholar
  38. 38.
    Motzer RJ, Mazumdar M, Bool GJ et al. (1996) High dose carboplatin etoposide and cyclophosphamide for patients with refractory germ cell tumors: treatment results and prognostic factors for survival and toxicity. J Clin Oncol 14: 1098–105.PubMedGoogle Scholar

Copyright information

© Springer-Verlag France, Paris 2006

Authors and Affiliations

  • S. Le Moulec
    • 1
  • A. Houlgatte
    • 2
  1. 1.Service d’oncologie-radiothérapieHäpital d’Instruction des Armées Val-de-GrâceParis Cedex 05
  2. 2.Service d’urologie du Pr HoulgatteHäpital d’Instruction des Armées du Val-de-GrâceParis Cedex 05

Personalised recommendations